Companies / Japan
Novartis Files Xolair In Japan
July 2006 | Product LaunchSwiss drug major Novartis has filed its Xolair asthma treatment in Japan. If approved, the monoclonal antibody will be Japan's first-in-class therapy for severe forms of the respiratory disorder. Xolair - which was developed with Roche-affiliated Genentech and US-based Tanox - was first approved in the US in 2003. Around 3,000 of Japan's 4mn asthmatics die from the disease each year, according to
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
